Search Results

• • 15 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.

  Authors:William C. Zamboni, Ramesh K. Ramanathan, Howard L. McLeod, Sridhar Mani, Douglas M. Potter, Sandra Strychor, et al.From:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006518 words Report

   Abstract Only

• Phase II study of vinflunine in patients with metastatic renal cell carcinoma.

  Authors:D. Goldstein, S. P. Ackland, D. R. Bell, I. N. Olver, I. D. Davis, M. A. Rosenthal, et al.From:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006348 words Report, Brief articl...

   Abstract Only

• A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies

  Authors:G. Schwartsmann, L.P. DiLeone, M. Horowitz, D. Schunemann, A. Cancella, A.S. Pereira, et al.From:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006 Clinical report 1690L

   Citation Only

• The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs

  Authors:Ada Rephaeli, Michal Entin-Meer, Dikla Angel, Nataly Tarasenko, Tal Gruss-Fischer, Irena Bruachman, et al.From:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006 Clinical report 1720L

   Citation Only

• Abraxane[R] induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency

  Authors:J. Lee Villano, Divyesh Mehta, and Latha RadhakrishnanFrom:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006 Article 1630L

   Citation Only

• Abraxane.sup.® induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency.

  Authors:J. Lee Villano, Divyesh Mehta, and Latha RadhakrishnanFrom:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 200655 words Report, Brief articl...

   Abstract Only

• Phase 1 trial of Anvirzel[TM] in patients with refractory solid tumors

  Authors:Tarek Mekhail, Hanspreet Kaur, Ram Ganapathi, G. Thomas Budd, Paul Elson, and Ronald M. BukowskiFrom:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006 Article 1440L

   Citation Only

• A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: a National Cancer Institute of Canada Clinical Trials Group trial

  Authors:M. Knowling, M. Blackstein, R. Tozer, V. Bramwell, J. Dancey, N. Dore, et al.From:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006 Article 1620L

   Citation Only

• The effect of single agent oral fusaric acid (FA) on the growth of subcutaneously xenografted SCC-1 cells in a nude mouse model

  Authors:James M. Ruda, Kirt S. Beus, Christopher S. Hollenbeak, Ronald P. Wilson, and Brendan C. Stack, Jr.From:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006 Clinical report 1540L

   Citation Only

• Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282

  Authors:Minaxi Jhawer, Sridhar Mani, Myrto Lefkopoulou, Richard G. Hahn, Jules Harris, Paul J. Catalano, et al.From:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006 Clinical report 1550L

   Citation Only

• A multi-center phase II study of BMS-247550 (ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane

  Authors:J.A. Ajani, H. Safran, C. Bokemeyer, M.A. Shah, H.-J. Lenz, E. Van Cutsem, et al.From:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006 Clinical report 1680L

   Citation Only

• Phase II study of vinflunine in patients with metastatic renal cell carcinoma

  Authors:D. Goldstein, S.P. Ackland, D.R. Bell, I.N. Olver, I.D. Davis, M.A. Rosenthal, et al.From:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006 Clinical report 1540L

   Citation Only

• Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer

  Authors:Milin R. Acharya, Judith E. Karp, Edward A. Sausville, Kyunghwa Hwang, Qin Ryan, Ivana Gojo, et al.From:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006 Article 1670L

   Citation Only

• Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes

  Authors:William C. Zamboni, Ramesh K. Ramanathan, Howard L. McLeod, Sridhar Mani, Duglas M. Potter, Sandra Strychor, et al.From:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006 Clinical report 1570L

   Citation Only

• Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx[R]) in combination with topotecan in patients with advanced malignancies

  Authors:Herve Ghesquieres, Sandrine Faivre, Latifa Djafari, Patricia Pautier, Catherine Lhomme, Stephanie Lozahic, et al.From:Investigational New Drugs (Vol. 24, Issue 5) Peer-Reviewed

  Sept. 2006 Clinical report 1450L

   Citation Only